HealthQuill US
The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between 18 and 59 years.
Drugs Health Pharma

US regulator gives nod for Moderna’s expanded use of mRNA vaccine

HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.

Read More
Appendiceal cancer tripled in Americans born between 1976 and 1984 and quadrupled for those born between 1981 and 1989, according to a study.
Drugs Health Research

Sharp rise in appendix cancer among Gen X,  millennials in US

HQ Team June 12, 2025: Appendiceal cancer tripled in Americans born between 1976 and 1984 and quadrupled for those born between 1981 and 1989,.

Read More
The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV) in infants up to one year of age for the first RSV season.
Drugs Health Pharma

Merck & Co.’s RSV injection for infants gets nod from US drug regulator

HQ Team June 10, 2025: The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV).

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales.

Read More
Paradromics Inc., a US-based neurotechnology company, has completed its first-in-human surgical placement of its brain-computer interface.
Drugs Health Medical

Paradromics places brain-computer device in human, rivals Neuralink

HQ Team June 5, 2025: Paradromics Inc., a US-based neurotechnology company, has completed its first-in-human surgical placement of its brain-computer interface. The safe.

Read More
Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.
Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products.

Read More
Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for a weight-loss drug candidate.
Drugs Health Pharma

Regeneron to pay China’s Hansoh $80m upfront for weight-loss drug

HQ Team June 2, 2025: Regeneron Pharmaceuticals, Inc. will pay China’s Hansoh Pharmaceuticals Group Company Limited $80 million upfront to acquire rights for.

Read More
Swiss-American Alcon Inc.’s acoltremon ophthalmic solution, Tryptyr, has received a green signal from the US Food and Drug Administration to treat dry eye disease.
Drugs Health Medical

Alcon’s medicine for dry eye disease gets approval from US regulator

HQ Team May 29, 2025: Swiss-American Alcon Inc.’s acoltremon ophthalmic solution, Tryptyr, has received a green signal from the US Food and Drug.

Read More
Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.
Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

Read More
The UN, facing a funding crisis following global budget cuts, is at risk of eroding its credibility and capacity to fulfil the mandates entrusted to it by its 193 members, delegates heard.
Drugs Health Medical

UN’s funding crisis risks credibility, capacity to meet global mandates

HQ Team May 20, 2025: The UN, facing a funding crisis following global budget cuts, is at risk of eroding its credibility and.

Read More